No abstract

Solitary fibrous tumor (SFT) has been rarely documented in the female genital tract. Until now, only 5 such cases have been reported in the vagina. A 40-yr-old referred to us with a history of antitubercular treatment and intra-abdominal adhesions; for which she previously underwent laparoscopic. Subsequently, she developed a vaginal mass, which appeared as a complex cyst on ultrasonogram. Histopathologic examination of the excised mass revealed a cellular spindle cell tumor with collagenous deposition in the stroma. The tumor cells were composed of oval to spindle shaped nuclei and were arranged in a diffuse, as well as in a focally, hemangiopercytomatous pattern. There were no significant mitotic figures or tumor necrosis. By immunohistochemistry, the tumor cells showed patchy positivity for CD34 and diffuse intranuclear positivity for STAT6, along with cytoplasmic positivity for MIC2 and BCL2. Few cells were estrogen receptor positive. MIB1/Ki67 highlighted 2% to 3% tumor nuclei (low). Diagnosis of a SFT was rendered. Subsequently, the tumor was subjected to molecular analysis, by reverse transcriptase-polymerase chain reaction and sequencing, which revealed presence of NAB2ex4-STAT6ex2 fusion transcript. This case constitutes the first case of a vaginal SFT confirmed by STAT6 immunostaining and NAB2-STAT6 fusion. It exemplifies the role of specific immunohistochemical markers, such as STAT6 in differentiating a SFT from various other spindle cell tumors occurring in this location. Literature review of similar reported cases and treatment implications in such cases are discussed.

No abstract

PURPOSE Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer. METHODS This study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations. RESULTS There were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene. CONCLUSION MTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations.